308283-47-8

Basic information

• Product Name: 3-BROMO-N-TERT-BUTYLBENZENESULPHONAMIDE
• Synonyms: 3-BROMO-N-TERT-BUTYLBENZENESULPHONAMIDE;N-TERT-BUTYL 3-BROMOBENZENESULFONAMIDE;3-Bromo-N-(tert-butyl)benzenesulphonamide 98%;3-bromo-N-tert-butylbenzenesulfonamide;BenzenesulfonaMide, 3-broMo-N-(1,1-diMethylethyl)-;3-Bromo-N-(tert-butyl)benzenesulphonamide98%
• CAS NO: 308283-47-8
• Molecular Formula: C₁₀H₁₄BrNO₂S
• Molecular Weight: 292.19
• Product Categories: blocks;Bromides;Sulfonamides
• Mol File: 308283-47-8.mol
• Article Data: 7

Chemical Properties

• Melting Point: 68-70
• Boiling Point: 365.3 °C at 760 mmHg
• Flash Point: 174.7 °C
• Appearance: /
• Density: 1.42 g/cm³
• Vapor Pressure: 1.58E-05mmHg at 25°C
• Refractive Index: 1.549
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.44±0.50(Predicted)
• CAS DataBase Reference: 3-BROMO-N-TERT-BUTYLBENZENESULPHONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-N-TERT-BUTYLBENZENESULPHONAMIDE(308283-47-8)
• EPA Substance Registry System: 3-BROMO-N-TERT-BUTYLBENZENESULPHONAMIDE(308283-47-8)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 308283-47-8(Hazardous Substances Data)

Usage

Description

3-BROMO-N-TERT-BUTYLBENZENESULPHONAMIDE is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceuticals. It is characterized by its unique chemical structure, which includes a benzene ring with a bromine atom at the 3-position and a tert-butyl group attached to the nitrogen atom of the sulfonamide functional group. 3-BROMO-N-TERT-BUTYLBENZENESULPHONAMIDE plays a significant role in the development of specific drugs targeting particular receptors in the human body.

Uses

Used in Pharmaceutical Industry:
3-BROMO-N-TERT-BUTYLBENZENESULPHONAMIDE is used as an intermediate for the preparation of benzamides, which are selective angiotensin II AT2 receptor agonists. These agonists have potential therapeutic applications in treating various conditions, such as hypertension, heart failure, and other cardiovascular diseases, by modulating the activity of the angiotensin II AT2 receptor.
3-BROMO-N-TERT-BUTYLBENZENESULPHONAMIDE's role as an intermediate in the synthesis of benzamides highlights its importance in the development of novel drugs with specific targeting capabilities. By understanding the compound's properties and potential applications, researchers and pharmaceutical companies can continue to innovate and create new treatments for a wide range of medical conditions.

InChI:InChI=1/C10H14BrNO2S/c1-10(2,3)12-15(13,14)9-6-4-5-8(11)7-9/h4-7,12H,1-3H3

Upstream product

• 2905-24-0 3-Bromobenzenesulfonyl chloride 
• 75-64-9 tert-butylamine 

Downstream Products

• 89599-01-9 3-bromobenzenesulfonamide 
• 936091-26-8 N-tert-butyl-3-{5-methyl-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-pyrimidin-4-ylamino}-benzenesulfonamide 
• 1310496-34-4 3-(4-(3-cyclopropyl-1H-pyrazol-5-ylamino)-5-bromopyrimidin-2-yl)-N-tert-butylbenzenesulfonamide 
• 706820-95-3 N-(tert-butyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide 
• 1059104-19-6 3-benzyl-N-tert-butyl-benzenesulfonamide 
• 1059104-16-3 N-tert-butyl-3-isobutylbenzenesulfonamide 
• 936091-56-4 N-tert-butyl-3-[5-methyl-2-(3-morpholin-4-ylmethyl-phenylamino)-pyrimidin-4-ylamino]-benzenesulfonamide 
• 936091-14-4 TG101209 
• 936092-53-4 N-(tert-butyl)-3-((2-chloro-5-methylpyrimidin-4-yl)amino)benzenesulfonamide 

Relevant articles and documents

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical composi

Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships

In the investigation of the structure-activity relationship of nonpeptide AT2 receptor agonists, a series of substituted benzamide analogues of the selective nonpeptide AT2 receptor agonist M024 have been synthesised. In a second ser

2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.